TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00460577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumerate
Description: 12 micrograms stat (twice if necessary). Inhaled via aerolizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenoterol/ipratropium bromide
Description: 0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
Study: NCT01436604

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage.

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage.
Study: NCT02469051

Intervention type: DEVICE
Group type: OTHER
Intervention: Breathhold SPECT-MPI
Description: Respiratory triggered SPECT myocardial perfusion imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard freebreathing SPECT-MPI
Description: Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary CT angiography
Description: Clinically indicated coronary CT angiography serving as standard of reference
Study: NCT02113540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT02961777

Intervention type: OTHER
Intervention: implementation of care pathway
Description: implementation of a care pathway

Intervention type: OTHER
Intervention: implementation of care pathway
Description: implementation of a care pathway
Study: NCT00223743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
Study: NCT03474341

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: * Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT
Study: NCT04611503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subretinal injection of rAAV.hPDE6A
Description: The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg).
Study: NCT03264599

Intervention type: DEVICE
Intervention: transabdominal ultrasound
Description: 2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk

Intervention type: DEVICE
Intervention: transabdominal ultrasound
Description: 2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
Study: NCT04232475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 minute of stair climbing and descending
Description: 1 minute of stair climbing and descending
Study: NCT03491462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matched placebo capsules taken 3 times daily
Study: NCT01575834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month (QM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month (QM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months (Q6M)
Study: NCT04101305

Intervention type: DIAGNOSTIC_TEST
Intervention: IsoPic
Description: Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: IsoPic
Description: Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: IsoPic
Description: Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: IsoPic
Description: Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
Study: NCT03756792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Education Material
Description: Patients will receive standard educational material about Mohs micrographic surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Education Material
Description: Patients will receive standard educational material about Mohs micrographic surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Education Material
Description: Patients will receive standard educational material about Mohs micrographic surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Education Material
Description: Patients will receive standard educational material about Mohs micrographic surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vignette
Description: Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vignette
Description: Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
Study: NCT01886924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Computer MI for Smoking Cessation
Description: Brief computer MI intervention to motivate tobacco quitline use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Control
Description: Computer delivered nutrition education control condition
Study: NCT03979573

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multiparametric MRI
Description: Multiparametric prostate MRI (mp-MRI)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Radiomics
Description: Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR-guided Biopsy
Description: MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular Markers
Description: Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
Study: NCT02361320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
Study: NCT04263311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW
Description: Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
Study: NCT01059565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
Study: NCT02525874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Initial oral dose for 7 days with maintenance dose thereafter
Study: NCT02794285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Study: NCT04437784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Trans-Abdominal Pre-Peritoneal
Description: Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pre-peritoneal repair
Description: Open pre-peritoneal single mesh repair with suture fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lichtenstein repair
Description: Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
Study: NCT02194270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride - soft pastille

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup - low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup - high dose
Study: NCT04014920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen group
Description: The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV Group
Description: The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
Study: NCT01659190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oiled-limestone liniment
Study: NCT04618185

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI to study gut function and transit without the risk of exposure to ionising radiation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI to study gut function and transit without the risk of exposure to ionising radiation.
Study: NCT01508039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chitin Micro Particle
Description: The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)
Study: NCT03671668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium bases using intra oral luting cement technique
Description: comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: titanium bases using intra oral luting cement technique
Description: comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
Study: NCT02519010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
Study: NCT00889538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mL of 1/2 normal saline IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutathione
Description: glutathione 600 mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutathione, vit C and NAC
Description: Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
Study: NCT00542802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
Study: NCT03902587

Intervention type: DEVICE
Intervention: Samsung's E-cervix technology
Description: While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
Study: NCT02738268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Study: NCT01260844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: briakinumab
Description: single dose briakinumab and 2 doses of CYP substrates
Study: NCT03142048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schools of Health for the Elderly
Description: The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing
Study: NCT01575834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months (Q6M)
Study: NCT05069116

Intervention type: OTHER
Intervention: Training in surgery
Description: The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.

Intervention type: OTHER
Intervention: Training in surgery
Description: The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
Study: NCT04232475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 minute of stair climbing and descending
Description: 3 minute of stair climbing and descending
Study: NCT02543905

Intervention type: PROCEDURE
Intervention: Prostate MRI and Biopsy
Description: All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.

Intervention type: PROCEDURE
Intervention: Prostate MRI and Biopsy
Description: All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.

Intervention type: PROCEDURE
Intervention: Prostate MRI and Biopsy
Description: All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
Study: NCT00454688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
Study: NCT02169141

Intervention type: OTHER
Intervention: Pharmacokinetics
Description: multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
Study: NCT04562246

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic assays for antibodies to SARS-CoV-2
Description: Beckman Coulter and Roche automated immunoassays
Study: NCT04232475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 minute of stair climbing and descending
Description: 10 minute of stair climbing and descending